The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations. (5th November 2015)

• Record Type: Journal Article
• Authors: Duryea, Elaine; Nicholson, Fiona; Cooper, Sara; Roberts, Scott; Rogers, Vanessa; McIntire, Donald; Sheffield, Jeanne; Stewart, Robert
• Other Names: Hafner Louise Academic Editor.
• Is Part Of: Infectious diseases in obstetrics and gynecology. Volume 2015(2015)
• Publication Date: 2015-11-05
• Subjects: Generative organs, Female -- Infections -- Periodicals; Communicable diseases in pregnancy -- Periodicals; 618.142005
• DOI: 10.1155/2015/563727
• Languages: English
• ISSNs: 1064-7449

Abstract

Abstract : Background . Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods . This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results . During the study period 1, 004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p < 0.001 . Conclusion . In this population with access to prenatal care and ART, treatment with protease inhibitors was associated with a greater fall in viral load, but not an increase in small or preterm infants.